Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 billion. BAQSIMI is indicated for the treatment of severe hypoglycemia, which is very low blood sugar, in people with diabetes aged four years and over. It is the first as […]
Roche is teaming up with Eli Lilly and Company (Lilly) to support the development of its Elecsys Amyloid Plasma Panel (EAPP) blood test which has been designed by the former to enable the earlier diagnosis of Alzheimer’s disease. According to Roche, to deal with the strain that Alzheimer’s disease has on healthcare systems, it is […]
Loxo@Lilly, the oncology division of Eli Lilly and Company (Lilly), has secured the accelerated approval of the US Food and Drug Administration (FDA) for Jaypirca (pirtobrutinib) for the treatment of mantle cell lymphoma (MCL). To be available in 100mg and 50mg tablets, Jaypirca is specifically indicated for the treatment of adult patients having relapsed or […]
Eli Lilly and Company (Lilly) is planning to invest an additional $450 million to increase the company’s production capacity at its Research Triangle Park facility in North Carolina. The proposed expansion is expected to help the American pharmaceutical company meet increased demand for its incretin products for diabetes and introduce the next generation of medicines. […]
Eagle Pharmaceuticals has secured an additional indication for Pemfexy (pemetrexed injection) in the US, marking the fifth indication for the intravenous medication. Pemfexy in combination with Merck’s Keytruda and platinum chemotherapy has been now approved by the US Food and Drug Administration (FDA) for the initial treatment of patients with metastatic, non-squamous, non-small cell lung […]
Lilly acquisition of Akouos : American pharmaceutical giant Eli Lilly and Company (Lilly) has agreed to acquire precision genetic medicine company Akouos in a cash deal worth about $487 million. Headquartered in Boston and founded in 2016, Akouos is focused on developing a portfolio of advanced adeno-associated viral gene therapies to treat inner ear conditions, […]
Eli Lilly and Company (Lilly) has been granted fast track designation for tirzepatide from the US Food and Drug Administration (FDA) for the treatment of adults having obesity, or are overweight with weight-associated comorbidities. Tirzepatide is a weekly once glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The American pharma giant said […]
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China suffering from difficult-to-treat cancers. The two parties plan to expedite the development and commercialization of a couple of important clinical stage oncology assets of Sanofi, which are SAR408701 (tusamitamab ravtansine; […]
Eli Lilly and Company (Lilly) said that it will invest $2.1 billion to build two new pharma manufacturing plants in Indiana, which will be located at the LEAP Lebanon Innovation and Research District in Boone County. According to the American pharma giant, the new plants will grow its manufacturing network for active ingredients and new […]
The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and Company (Lilly)’s sintilimab injection in nonsquamous non-small cell lung cancer (NSCLC). Lilly has been issued a complete response letter (CRL) for the BLA for the PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy. The US pharma […]